Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis

Figure 2

3-year survival depending on primary tumor. Overall survival of patients with appendiceal cancer (n = 11) vs. patients with colorectal cancer (n = 21) as primary tumor. 3-year survival rates: 72.7% (AC) and 47.6% (CRC). p = 0.213 (n.s.). AC = appendiceal cancer, CRC =  colorectal cancer.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us